Journal of Cachexia, Sarcopenia and Muscle · Nov 15, 2026
Effectiveness of a Nutritional Supplement With Anti‐Inflammatory Compounds and Olive Oil in Malnourished Patients
By Vidal‐Casariego A, Gómez JJL, Almeida JMG et al.
Background: Disease‐related malnutrition (DRM) with systemic inflammation is associated with poor clinical outcomes and muscle mass loss. This study in a real‐world clinical practice examined whether an oral nutritional supplement (ONS) enriched with anti‐inflammatory compounds—eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and extra‐virgin olive oil (EVOO)—was associated with improvements in nutritional status, muscle mass and functional performance in patients with inflammation‐related DRM. Methods: In this 12‐week prospective multicenter cohort study, adults diagnosed with DRM and elevated C‐reactive protein (CRP > 3 mg/L) received either an anti‐inflammatory ONS or standard ONS, both combined with dietary counselling and a structured physical activity programme. Outcomes included anthropometry, body composition (bioimpedance and ultrasound), muscle function, inflammatory markers and quality of life. Results: Of 266 participants (mean age 66.6 ± 12.9 years; 61.7% male), those receiving the anti‐inflammatory ONS ( n = 165) achieved significantly greater increases in fat‐free mass (Δ +1.20 vs. −0.85 kg; p = 0.022), skeletal muscle index (Δ +0.12 vs. −0.21 kg/m ² ; p = 0.022) and rectus femoris circumference by ultrasound (Δ +0.43 vs. −0.13 cm; p = 0.042) compared with controls ( n = 101). Functional improvements were also superior: Chair stand repetitions increased significantly (Δ +0.90 vs. +0.03 times; p = 0.025), with a trend toward reduced Timed Up and Go time. Quality of life improved significantly across physical and mental domains in the anti‐inflammatory group (e.g., VAS: Δ +11.1 vs. −10.8; p < 0.001). After adjustment for baseline values, age, sex, GLIM severity, CRP and primary diagnosis, differences remained significant for SMI (0.10 kg/m ² ; 95% CI, 0.01–0.19), fat‐free mass, muscle circumference, chair stand and EQ VAS (12.85 points; 95% CI, 5.61–20.08), but not for handgrip strength. Twelve‐week mortality was higher with the anti‐inflammatory ONS (11.5% vs. 4.95%; adjusted OR, 3.35; 95% CI, 1.06–13.81). Conclusions: In this post hoc analysis, the use of an ONS enriched with EPA, DHA and EVOO, combined with physical activity and dietary counselling, was associated with greater gains in muscle mass, lower‐limb strength and quality of life in patients with inflammation‐associated DRM, but also with higher short‐term mortality. Because residual confounding cannot be excluded, these findings are hypothesis‐generating; randomized controlled trials with prespecified safety outcomes are needed.
doi.org/10.1002/jcsm.70417Open accessPubMed 43036224Interventions